Death Reported In Phase II Trial For Astellas/FibroGen's Oral EPO Candidate
This article was originally published in PharmAsia News
Executive Summary
Astellas/FibroGen have observed one fatality in a Phase II trial of the oral anemia treatment candidate FG-2216, Astellas reported May 7. The cause of death was fulminant hepatitis, and FDA has been notified